Our therapy is clinically validated.
Immetacyte has used TIL successfully to treat metastatic cutaneous melanoma patients, who have failed other standard treatments (including checkpoint inhibitors). We have demonstrated that our therapy produces major tumour responses in around 50% of these patients and durable remissions leading to potential cures in around 20% of patients.
We have also seen responses in small number of other subtypes of melanoma treated.
Trials in platinum resistant ovarian cancer and cutaneous melanoma are planned - formal announcements pending.
Immetacyte has a programme of next generation TIL-based products in pre-clinical evaluation to further enhance efficacy, allow for commercial manufacture scale-up, reduce treatment costs and improve patient experience by reducing toxicities associated with the supporting drugs..